Novel players in multiple myeloma pathogenesis: Role of protein kinases CK2 and GSK3

Leukemia Research

Volumn 37, Issue 2, 2013, Pages 221-227

  Piazza, Francesco ^a,b   Manni, Sabrina ^a,b   Semenzato, Gianpietro ^a,b  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bone disease; ER stress UPR response; Multiple myeloma; NF B; Protein kinase CK2; Protein kinase GSK3; STAT3; Targeted therapy

Indexed keywords

APIGENIN; CASEIN KINASE II; CELL CYCLE PROTEIN 37; DICKKOPF 1 PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; STAT3 PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR MAFA; TRANSCRIPTION FACTOR MAFB; X LINKED INHIBITOR OF APOPTOSIS;

BONE DISEASE; CANCER CELL; CANCER GROWTH; CATALYSIS; CELL SURVIVAL; CHROMOSOME TRANSLOCATION; DNA DAMAGE; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; MULTIPLE MYELOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE; UPREGULATION;

ANIMALS; BONE DISEASES; CASEIN KINASE II; CELL SURVIVAL; ENDOPLASMIC RETICULUM STRESS; GLYCOGEN SYNTHASE KINASE 3; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MULTIPLE MYELOMA; NF-KAPPA B; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84872399759     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.10.016     Document Type: Review

References (44)

1. Raab M.S., Podar K., Breitkreutz I., Richardson P.G., Anderson K.C. Multiple myeloma. Lancet 2009, 374(July (9686)):324-339.
2. Ocio E.M., Mateos M.V., Maiso P., Pandiella A., San-Miguel J.F. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008 Dec, 9(12):1157-1165.
3. Mitsiades C.S., Hideshima T., Chauhan D., McMillin D.W., Klippel S., Laubach J.P., et al. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol 2009, 46(April (2)):166-175.
4. Morgan G.J., Walker B.A., Davies F.E. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012, 12(May (5)):335-348.
5. Anderson K.C., Carrasco R.D. Pathogenesis of myeloma. Annu Rev Pathol 2011, 6:249-274.
6. Chesi M., Bergsagel P.L. Many multiple myelomas: making more of the molecular mayhem. Hematology/Am Soc Hematol Educ Program 2011, 2011:344-353.
7. Hideshima T., Anderson K.C. Novel therapies in MM: from the aspect of preclinical studies. Int J Hematol 2011, 94(October (4)):344-354.
8. Ruzzene M., Pinna L.A. Addiction to protein kinase CK2: a common denominator of diverse cancer cells?. Biochim Biophys Acta 2010, 1804(March (3)):499-504.
9. Patel S., Doble B., Woodgett J.R. Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword?. Biochem Soc Trans 2004, 32(November (Pt 5)):803-808.
10. Chen L.F., Greene W.C. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 2004, 5(May (5)):392-401.
11. Channavajhala P., Seldin D.C. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene 2002, 21(August (34)):5280-5288.
12. Kitagawa K., Kotake Y., Hiramatsu Y., Liu N., Suzuki S., Nakamura S., et al. GSK3 regulates the expressions of human and mouse c-Myb via different mechanisms. Cell Div 2010, 5:27.
13. Piazza F., Manni S., Colpo A., Tubi L.Q., Gurrieri C., Semenzato G. Serine-threonine protein kinases CK1, CK2 and GSK3 in normal and malignant haematopoiesis. Curr Signal Transd Ther 2011, 6(January (1)):88-98.
14. Trembley J.H., Wang G., Unger G., Slaton J., Ahmed K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci 2009, 66(June (11-12)):1858-1867.
15. Ahmad K.A., Wang G., Unger G., Slaton J., Ahmed K. Protein kinase CK2, a key suppressor of apoptosis. Adv Enzyme Regul 2008, 48:179-187.
16. Ruzzene M., Pinna L.A. Addiction to protein kinase CK2: a common denominator of diverse cancer cells?. Biochim Biophys Acta 2010 Mar, 1804(3):499-504.
17. Piazza F., Manni S., Ruzzene M., Pinna L.A., Gurrieri C., Semenzato G. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia 2012, 26(6):1174-1179.
18. Piazza F.A., Ruzzene M., Gurrieri C., Montini B., Bonanni L., Chioetto G., et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 2006 Sep 1, 108(5):1698-1707.
19. Davenport E.L., Moore H.E., Dunlop A.S., Sharp S.Y., Workman P., Morgan G.J., et al. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 2007, 110(October (7)):2641-2649.
20. Rutkowski D.T., Hegde R.S. Regulation of basal cellular physiology by the homeostatic unfolded protein response. J Cell Biol 2010, 189(May (5)):783-794.
21. Papandreou I., Denko N.C., Olson M., Van Melckebeke H., Lust S., Tam A., et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 2010, 117(January (4)):1311-1314.
22. Miyata Y., Nishida E. CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37. Mol Cell Biol 2004, 24(May (9)):4065-4074.
23. Manni S., Brancalion A., Tubi L.Q., Colpo A., Pavan L., Cabrelle A., et al. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response. Clin Cancer Res: Off J Am Assoc Cancer Res 2012, 18(April (7)):1888-1900.
24. Zhao M., Ma J., Zhu H.Y., Zhang X.H., Du Z.Y., Xu Y.J., et al. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2 Cdc37 and Hsp90. Mol Cancer 2011, 10:104.
25. Hessenauer A., Schneider C.C., Gotz C., Montenarh M. CK2 inhibition induces apoptosis via the ER stress response. Cell Signal 2011, 23(January (1)):145-151.
26. Hosoi T., Korematsu K., Horie N., Suezawa T., Okuma Y., Nomura Y., et al. Inhibition of casein kinase 2 modulates XBP1-GRP78 arm of unfolded protein responses in cultured glial cells. PLoS One 2012, 7(6):e40144.
27. Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001, 359(October (Pt 1)):1-16.
28. Rayasam G.V., Tulasi V.K., Sodhi R., Davis J.A., Ray A. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 2009 Mar, 156(6):885-898.
29. Kim L., Kimmel A.R. GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin Genet Dev 2000, 10(October (5)):508-514.
30. Jope R.S., Yuskaitis C.J., Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007, 32(April-May (4-5)):577-595.
31. Hoeflich K.P., Luo J., Rubie E.A., Tsao M.S., Jin O., Woodgett J.R. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000, 406(July (6791)):86-90.
32. G-Amlak M., Uddin S., Mahmud D., Damacela I., Lavelle D., Ahmed M., et al. Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. Biochem Biophys Res Commun 2002, 297(October (4)):760-764.
33. Zhou Y., Uddin S., Zimmerman T., Kang J.A., Ulaszek J., Wickrema A. Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk Lymphoma 2008, 49(October (10)):1945-1953.
34. Rocques N., Abou Zeid N., Sii-Felice K., Lecoin L., Felder-Schmittbuhl M.P., Eychene A., et al. GSK-3-mediated phosphorylation enhances Maf-transforming activity. Mol Cell 2007, 28(November (4)):584-597.
35. Piazza F., Manni S., Tubi L.Q., Montini B., Pavan L., Colpo A., et al. Glycogen synthase kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. BMC Cancer 2010, 10:526.
36. Busino L., Millman S.E., Scotto L., Kyratsous C.A., Basrur V., O'Connor O., et al. Fbxw7alpha- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol 2012, 14(April (4)):375-385.
37. Heider U., Hofbauer L.C., Zavrski I., Kaiser M., Jakob C., Sezer O. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem Biophys Res Commun 2005, 338(December (2)):687-693.
38. Gavriatopoulou M., Dimopoulos M.A., Christoulas D., Migkou M., Iakovaki M., Gkotzamanidou M., et al. Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opin Ther Targets 2009, 13(July (7)):839-848.
39. Krause U., Harris S., Green A., Ylostalo J., Zeitouni S., Lee N., et al. Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. Proc Natl Acad Sci USA 2010, 107(March (9)):4147-4152.
40. Gunn W.G., Krause U., Lee N., Gregory C.A. Pharmaceutical inhibition of glycogen synthetase kinase-3beta reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model. Blood 2011, 117(February (5)):1641-1651.
41. Siddiqui-Jain A., Drygin D., Streiner N., Chua P., Pierre F., O'Brien S.E., et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 2010, 70(December (24)):10288-10298.
42. Pierre F., Chua P.C., O'Brien S.E., Siddiqui-Jain A., Bourbon P., Haddach M., et al. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol Cell Biochem 2011, 356(October (1-2)):37-43.
43. Siddiqui-Jain A., Bliesath J., Macalino D., Omori M., Huser N., Streiner N., et al. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther 2012, 11(April (4)):994-1005.
44. Beurel E., Jope R.S. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006, 79(July (4)):173-189.